Study finds no overall survival benefit, but improved quality of life with talazoparib in advanced BRCA-mutated breast cancer
Phase III EMBRACA trial survival benefit results may be affected by subsequent treatmentsCredit: MD Anderson Cancer Center HOUSTON - New ...




















